This article has been updated with additional details about the ClonoSIGHT test and to clarify that Sequenta is in discussions with the FDA to transition the diagnostic from a lab test to a kit.

Increasingly sensitive diagnostics that can help researchers and healthcare providers track leukemia patients who have achieved remission and those who are relapsing after treatment are becoming an important tool in the treatment of these illnesses and the development of new drugs.